VLP BioTech, Inc. Announces an Immunotherapy Designed for the ...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
SAN DIEGO, Feb. 24, 2021 /PRNewswire-AsiaNet/ -- -VLP BioTech Has Developed a Vaccine-Based Viral-Entry-Inhibitor for the Treatment of Chronic HBV/HDV. -The Vaccine-Based Treatment Has Significant Advantages Compared to a Peptide-Based, Entry-Inhibitor (Hepcludex).VLP BioTech, Inc., ...
Authors: LATEST ASIANET NEWS RELEASES